Invitrogen said Tuesday it will spend approximately $386 million to purchase privately held Dynal Biotech of Oslo, Norway.

The proposed acquisition, which includes Dynal’s Dynabeads magnetic separation-technology business as well as its HLA diagnostics segment, would move Invitrogen for the first time into an FDA-regulated market and potentially give it access to Dynal’s in vitro diagnostics customers like Roche Diagnostics and Bayer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.